Delcath Systems (NASDAQ:DCTH) Director Sells $488,475.00 in Stock

Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) Director Bridget Martell sold 22,500 shares of the stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $21.71, for a total value of $488,475.00. Following the completion of the sale, the director owned 22,500 shares of the company’s stock, valued at $488,475. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Delcath Systems Price Performance

Shares of Delcath Systems stock opened at $20.55 on Monday. The stock’s 50-day simple moving average is $15.88 and its 200-day simple moving average is $12.70. Delcath Systems, Inc. has a 52 week low of $8.12 and a 52 week high of $22.51. The company has a market capitalization of $714.89 million, a price-to-earnings ratio of 128.44 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. The firm had revenue of $35.10 million during the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. On average, equities analysts expect that Delcath Systems, Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DCTH shares. BTIG Research lifted their price objective on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Zacks Research upgraded shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 11th. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Thursday. HC Wainwright raised their target price on shares of Delcath Systems from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Finally, Wall Street Zen upgraded shares of Delcath Systems from a “buy” rating to a “strong-buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $29.33.

View Our Latest Stock Analysis on DCTH

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in DCTH. Marshall Wace LLP boosted its stake in Delcath Systems by 69.8% during the third quarter. Marshall Wace LLP now owns 371,893 shares of the company’s stock valued at $5,939,000 after buying an additional 152,930 shares during the last quarter. Jump Financial LLC increased its stake in Delcath Systems by 6.3% in the 3rd quarter. Jump Financial LLC now owns 93,589 shares of the company’s stock worth $1,495,000 after acquiring an additional 5,554 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after acquiring an additional 21,069 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Delcath Systems in the 2nd quarter worth approximately $1,362,000. Finally, Alps Advisors Inc. raised its holdings in shares of Delcath Systems by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after acquiring an additional 10,600 shares in the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Delcath Systems

These are some of the DCTH headlines that stood out recently:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $36 price target, raising its FY2026 EPS forecast from a loss of $0.17 to earnings of $0.13 and its FY2027 estimate from $0.12 to $0.33. It also expects a narrower Q4 2026 loss. MarketBeat analyst estimates
  • Positive Sentiment: Recent coverage highlighted better-than-expected earnings; the provided results show EPS of $0.17 versus a $0.09 loss expected and revenue of $35.1 million versus a $26.0 million consensus. Earnings coverage
  • Neutral Sentiment: Delcath will be featured on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The coverage may raise awareness, but no direct commercial or financial impact was disclosed. BioSpace announcement

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Featured Articles

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.